ReviewJournal of neurology2014
Dopamine receptor mapping with PET imaging in Parkinson's disease.
Review in Journal of neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism.European journal of nuclear medicine and molecular imaging · 2016Pooled it
- Brain connectivity markers in advanced Parkinson's disease for predicting mild cognitive impairment.European radiology · 2021Trial
- Synaptojanin1 regulates synaptic dopamine release and axonal integrity via retromer-dependent endosomal sorting.Research square · 2026Article
- The Binding of the High Affinity Radioligand Fallypride to the D2-dopamine Receptor is Sensitive to Injected Mass - a PET Study in Rodents.Molecular imaging and biology · 2026Article
- Parkinson's Disease Patient-Specific Striatum Organoids Show Hallmarks of Increased Inflammation.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.Brain : a journal of neurology · 2026Review
- Parkinson's Disease: From Bench to Bedside-Advancements in Diagnosis and Therapeutics using Pharmacogenomic Approach.Current gene therapy · 2026Review
- Synaptojanin-1 supports VPS35-dependent trafficking of dopamine D2 autoreceptors at presynaptic terminals.Research square · 2025Article
- Dopamine D2 receptor upregulation in dorsal striatum in the LRRK2-R1441C rat model of early Parkinson's disease revealed by in vivo PET imaging.Scientific reports · 2025Article
- Automatic differentiation of Parkinson's disease motor subtypes based on deep learning and radiomics.Frontiers in neurology · 2025Article
- Frontal-striatal glucose metabolism and fatigue in patients with multiple sclerosis, long COVID, and COVID-19 recovered controls.Experimental brain research · 2024Article
- Pain in Parkinson's disease: a neuroanatomy-based approach.Brain communications · 2024Review
- Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Reliability and Validity of Power Spectrum Slope (PSS): A Metric for Measuring Resting-State Functional Magnetic Resonance Imaging Activity of Single Voxels.Frontiers in neuroscience · 2022Article
- Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer's disease.Journal of nanobiotechnology · 2021Article
- Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinson's Patients, Using In VivoMetabolites · 2021Article
- Detecting G protein-coupled receptor complexes in postmortem human brain with proximity ligation assay and a Bayesian classifier.BioTechniques · 2020Article
- Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease.Aging cell · 2019Review
- Improved synthesis of [EJNMMI radiopharmacy and chemistry · 2019Article
- Disentangling the diverse roles of dopamine D2 receptors in striatal function and behavior.Neurochemistry international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Parkinson's disease (PD) is a chronic neurodegenerative disorder characterised pathologically by the loss of dopaminergic neurons in the substantia nigra pars compacta. These neurons project to the striatum, and their loss leads to alterations in the activity of the neural circuits that regulate movement. The striatal output of the circuit related to the control of movement is mediated by two pathways: the direct striatal pathway, which is mediated through facilitation of D1 receptors, and the indirect striatal pathway, mediated through D2 receptors. Positron emission tomography (PET) molecular imaging is a powerful in vivo technique in which using selective dopaminergic radioligands has been employed to investigate the dopaminergic system in humans. In this article we aim to review the role of PET imaging in understanding the postsynaptic dopaminergic mechanisms in PD. PET studies have allowed us to gain important insights into the functions of the dopaminergic system, the mechanisms of drug-induced motor and non-motor complications, and the placebo effect in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.